Akari Therapeutics (AKTX) Cash & Equivalents (2011 - 2026)

Akari Therapeutics has disclosed Cash & Equivalents across 16 years of filings, most recently posting $2.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $2.8 million, up 4.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (up 4.77% YoY), and the FY2025 annual result was $5.2 million, up 95.68% from the prior year.
• Cash & Equivalents came in at $2.8 million for Q1 2026 at Akari Therapeutics, down from $5.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $13.2 million in Q4 2022 to a low of $162567.0 in Q3 2025.
• The 5-year median for Cash & Equivalents is $2.7 million (2025), against an average of $3.7 million.
• Peak annual rise in Cash & Equivalents reached 101.68% in 2025, while the deepest fall reached 92.76% in 2025.
• Akari Therapeutics' Cash & Equivalents stood at $13.2 million in 2022, then tumbled by 70.98% to $3.8 million in 2023, then slumped by 30.85% to $2.7 million in 2024, then jumped by 95.68% to $5.2 million in 2025, then sank by 46.8% to $2.8 million in 2026.
• The last three Cash & Equivalents figures came in at $2.8 million (Q1 2026), $5.2 million (Q4 2025), and $162567.0 (Q3 2025), per Business Quant data.